Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.9
5.2
Journals
Vaccines
Special Issues
Next Generation Sequencing: A Promising Tool for Vaccines and Other...
share announcement

Next Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".

Deadline for manuscript submissions: closed (10 November 2023) | Viewed by 3040

Special Issue Editors

Dr. Srinivas Nellimarla

E-Mail Website
Guest Editor
Department of Molecular and Cellular Biology, University of Guelph, 50 Stone Rd E, Guelph, ON N1G 2W1, Canada
Interests: molecular biology; virology; vaccines; gene editing and gene therapy
Dr. Prasad Kesanakurti

E-Mail Website
Guest Editor
College of Biological Sciences, University of Guelph, Guelph, ON N1G 2W1, Canada
Interests: molecular biology; next-generation sequencing; viral vectors

Special Issue Information

Dear Colleagues,

The recent outbreak of the novel coronavirus, SARS-CoV-2, and the disease caused by this virus, COVID-19, has become one of the most deadly pandemics in history, and has exposed the weakness of our surveillance system to effectively respond to the emergence of highly contagious and lethal viruses. However, it has also provided an opportunity to use genomic technologies for the rapid development of vaccines. Next-generation sequencing (NGS) has been proved to be a powerful high-throughput tool for strengthening our surveillance system through the genetic detection and characterization of infectious agents, as well as the identification of outbreaks and spill-over events. NGS aided the development of vaccines based on mRNA and DNA, the development of antiviral drugs and even the detection of minor variants based on either the partial- or whole-genome sequencing of any viral agent. It has shown great potential for adventitious agent testing through the successful identification of known and novel viruses, transforming the quality assessment of vaccines and other biological products. Although NGS technology has broad applications from vaccine development to quality assessment, the development of validated sequencing methods that meet regulatory standards is still an ongoing process, which provides a great opportunity to refine method development and further increase the usage of this technology in biologics.

We are pleased to invite authors to contribute to this Special Issue focused on topics relevant to the theme “Next-Generation Sequencing: a promising tool for vaccines and other biological products”. This Special Issue aims to gather a comprehensive collection of articles that report key developments and emerging concepts in the area of next-generation sequencing related to the understanding of viral infections and vaccines.

This Special Issue will feature all types of manuscripts, including reviews, research articles, and short communications. The topics may include (but are not restricted to) recent advances of NGS in monitoring and characterizing viral agents, screening for mutations impacting viral pathogenesis, identifying viral proteins to design antiviral drugs, studying the origin of pandemics, and new insights in NGS in vaccine development and viral immune evasion.

We look forward to receiving your contributions.

Dr. Srinivas Nellimarla
Dr. Prasad Kesanakurti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • next-generation sequencing
  • viruses
  • pandemics
  • vaccines
  • antivirals
  • immune response

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Review

3 pages, 180 KiB  
Editorial
Next-Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products
by Srinivas Nellimarla and Prasad Kesanakurti
Vaccines 2023, 11(3), 527; https://doi.org/10.3390/vaccines11030527 - 23 Feb 2023
Cited by 1 | Viewed by 1360
Abstract
Next-generation sequencing (NGS), also known as high-throughput sequencing (HTS), is a commonly used term to represent a set of DNA sequencing technologies that have been in use for almost two decades [...] Full article
(This article belongs to the Special Issue Next Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products)

Review

Jump to: Editorial

26 pages, 754 KiB  
Review
Potential Intersections between lncRNA, Vascular Cognitive Impairment, and Immunization Strategies: Insights and Future Directions
by Yishu Fan, Bo Xiao and Mengqi Zhang
Vaccines 2024, 12(3), 251; https://doi.org/10.3390/vaccines12030251 - 28 Feb 2024
Cited by 1 | Viewed by 1253
Abstract
Vascular cognitive impairment (VCI) encompasses a wide range of cognitive disorders stemming from cerebrovascular issues, such as strokes or small vessel disease. These conditions often pose challenges to traditional diagnostic approaches due to their multifactorial nature and varied clinical presentations. Recently, next-generation sequencing [...] Read more.
Vascular cognitive impairment (VCI) encompasses a wide range of cognitive disorders stemming from cerebrovascular issues, such as strokes or small vessel disease. These conditions often pose challenges to traditional diagnostic approaches due to their multifactorial nature and varied clinical presentations. Recently, next-generation sequencing (NGS) technologies have provided detailed analyses of long non-coding RNAs (lncRNAs) in the molecular pathobiology of VCI. These new findings help with molecular-based diagnostics and treatments of VCI. Within this realm, the concept of immune modulation, especially through specific vaccinations, emerges as a promising therapeutic strategy in VCI mitigation. In this review, we comprehensively elucidate the function of lncRNAs in VCI, emphasizing the advanced understanding of VCI’s molecular underpinnings made possible through NGS technologies. Significant focus is placed on the immune system’s role in VCI, particularly the neuroinflammatory processes which are consequential to cerebrovascular abnormalities. We believe that lncRNAs participate in regulating these immunological pathways, potentially guiding the development of vaccines targeting VCI. In this context, we propose a novel perspective: using knowledge about lncRNA profiles and functions to guide vaccine development, we can potentially exploit the body’s immune response to mitigate or prevent VCI. This approach has the potential to revolutionize VCI management by introducing targeted immunization strategies informed by molecular signatures, a concept that remains largely unexplored in current research endeavors. In addition, we summarize current progress and propose future directions, advocating for robust, interdisciplinary studies to validate the potential intersections between lncRNA landscapes, VCI pathology, and immunology. This review aims to spur innovative research and promote the development of lncRNA-informed vaccine strategies as proactive interventions against the cognitive consequences of VCI. Full article
(This article belongs to the Special Issue Next Generation Sequencing: A Promising Tool for Vaccines and Other Biological Products)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop